AVANT BIO

AVANT BIO is a growth equity firm dedicated to advancing transformative therapies by investing in companies developing enabling technologies in the life sciences sector. The firm partners with innovators at the intersection of advanced technologies and novel therapeutics to accelerate the development of game-changing treatments. Their investment focus spans from early-stage to late-stage companies, fostering new growth and innovation at various stages of company development. AVANT BIO's unique approach lies in its ability to catalyze value through disciplined investment strategies backed by industry expertise. The firm's extensive network serves as a gateway to accelerated growth opportunities for its portfolio companies. With a commitment to amplifying value and a forward-looking investment strategy, AVANT BIO is primed to unlock the full potential of the upcoming advancements in life sciences, tech bio, and health tech. Setting itself apart in a traditionally male-dominated industry, AVANT BIO is led by Daniella Kranjac, a visionary woman and vanguard in the life sciences and private equity landscapes.

AVANT BIO's portfolio includes investments in companies such as Nomic Bio, PathPresenter, and PL BioScience, reflecting its commitment to supporting innovative solutions in healthtech, life sciences research, and drug development. The firm's leadership team comprises experienced professionals, including Founding General Partner Daniella Kranjac, Partner Reinhard Vogt, and Partner Sebastien Latapie, who was promoted to Partner in January 2025. Their combined expertise and strategic vision position AVANT BIO as a leading equity firm in the life sciences, tech bio, and healthtech sectors.

With a focus on therapeutic enabling technologies, AVANT BIO actively partners with visionary entrepreneurs to maximize value creation. The firm provides connections, deep expertise, and long-term guidance to bring innovative ideas to life and drive transformative therapies. Their investment philosophy emphasizes the convergence of groundbreaking technologies and an enhanced understanding of biology, creating a powerful synergy poised for breakthrough advancements in the future.